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Background: The limited success of recent HIV topical pre-exposure prophylaxis clinical trials highlights the need
for more predictive models of drug efficacy that better simulate what may happen during sexual exposure. To
address this gap, we developed complementary in vitro models to evaluate the ability of drugs to retain anti-HIV
activity if cells were washed with seminal plasma (simulating what may happen following exposure to ejaculate),
and to protect drug-naive T cells (representing newly recruited immune cells) co-cultured with explants that had
been pretreated with drug. We focused on tenofovir disoproxil fumarate (TDF), the non-nucleoside reverse
transcriptase inhibitors dapivirine (DPV) and IQP-0528, and the entry inhibitors maraviroc (MVC) and the D-peptide
chol-PIE-12 trimer (PIE12). Studies were extended to macaques and the ability of cervical biopsies obtained from
animals treated with an intravaginal ring formulation of IQP-0528 to protect ex vivo co-cultured T cells was
determined. The antiviral activity of cervicovaginal lavage samples against a primary Clade C isolate was also
measured and correlated with drug levels.
Results: Cells exposed to TDF were equally protected from HIV whether or not the drug-treated cells were washed
with medium or seminal plasma prior to challenge. In contrast, several-fold higher concentrations of NNRTIs and
entry inhibitors were needed to attain similar levels of HIV inhibition following a wash with seminal plasma.
Conversely, the NNRTIs and PIE12, but not TDF or MVC, were effectively transferred from ex vivo treated explants
and protected co-cultured T cells. Biopsies obtained from IQP-0528 ring-treated macaques also protected co-
cultured T cells with viral inhibition ranging from 42-72%. Antiviral activity correlated with the concentration of
drug recovered. Combinations of TDF with IQP-0528 protected in both in vitro models.
Conclusions: Together, these models suggest that intracellularly retained drugs such as TDF may protect resident
immune cells following coitus but sustained delivery may be required to protect immune cells subsequently
recruited into the genital tract. Sustained delivery may also be critical for NNRTIs, which are rapidly transported out
of cells and could be lost following sexual intercourse. An ideal approach may be a combination of drugs with
complementary bioavailability profiles formulated for sustained delivery.
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The development and implementation of strategies to
prevent HIV and other sexually transmitted infections
(STI) in high-risk populations are a public health im-
perative. There have been several successes in the battle
to develop safe and effective prevention modalities,
including oral or topical pre-exposure prophylaxis
(PrEP), as highlighted by the recent FDA approval of
oral Truvada, a fixed-dose combination of two reverse
transcriptase inhibitors (RTIs): tenofovir disoproxil fu-
marate (TDF) and emtricitabine. Orally administered
Truvada or TDF provided significant, albeit variable,
protection in four separate clinical trials [1-4], but was
ineffective in two others [5,6], likely reflecting poor ad-
herence by study participants [7]. Encouraging results
were also obtained in a clinical trial with 1% tenofovir
(TFV) gel applied vaginally before and after coitus [8].
However, in a subsequent trial, daily application of the
same TFV gel formulation was not protective; the disap-
pointing outcome was attributed, at least in part, to poor
adherence [9]. Together, these studies illustrate that it is
clearly possible to prevent sexual transmission with top-
ical application of antiretrovirals (ARVs) but low adher-
ence to the gel treatment regimens may impede the
ability to measure efficacy. Thus, the challenge in estab-
lishing a clinically efficacious HIV prevention method
may be largely rooted in both human behavior and
biology.
The formulation of PrEP has the potential to address
both the behavioral and biological determinants of HIV
prevention. Sustained delivery systems, for example, may
promote adherence, but efficacy may also be impacted
by the ability of the formulation to deliver and maintain
sufficient concentration of drug at the sites of infection.
For example, while bioactive drug was detected in
cerviocovaginal lavage (CVL) samples obtained from
women who applied 0.5% PRO 2000 gel in the absence
of sex, there was a significant reduction in the concen-
tration of drug recovered and the anti-HIV activity of
CVL in samples obtained shortly after coitus [10]. We
speculate that the observed reduction in anti-HIV activ-
ity of postcoital CVL samples reflected drug loss due to
leakage, redistribution and dilution with ejaculate. At the
molecular level, activity was likely reduced due to inter-
actions of the drug with molecules present in semen that
altered PRO 2000’s ability to bind to viral glycoproteins
[11] and thus contributed to the failure of the drug to
protect against HIV (or HSV-2) acquisition [12].
In the current study, we sought to determine the
in vitro efficacy of a number of PrEP ARVs using com-
plementary models designed to evaluate the pharmaco-
kinetics (PK) and pharmacodynamics (PD) of drugs. The
models focused on the potential washout effects of an
ejaculate and the need to protect both resident andimmune cells recruited into the genital tract. The im-
portance of newly recruited immune cells is illustrated
by the observation that there is an increase in HIV target
cells including monocyte/macrophages and dendritic
cells in cervical biopsies following unprotected sexual
intercourse compared to samples obtained from abstin-
ent women [13]. We tested these in vitro models using
drugs being advanced as topical PrEP candidates that
differ in site (cell surface or intracellular) and mechan-
ism (reverse transcriptase inhibitors (RTIs) and entry
inhibitors), as well as need for intracellular modifications
(e.g., phosphorylation of TFV). The drugs included TDF,
the more potent prodrug of TFV that exhibits greater
cellular uptake than TFV and has recently been success-
fully formulated as an IVR and shown complete protec-
tion in a repeat low dose macaque challenge model
[14,15]; the non-nucleoside RTIs (NNRTIs), dapivirine
(DPV) and IQP-0528, which have both been formulated
as gels and IVRs [16-19] and, unlike TDF/TFV, do not
require intracellular modification; and two entry inhibi-
tors: maraviroc (MVC), a CCR5 coreceptor antagonist,
which is being evaluated in clinical trials as an IVR alone
and in combination with DPV, and a cholesterol-
modified D-peptide that targets the HIV gp41 N-trimer
pocket, chol-PIE-12 trimer (PIE12), which is in formula-
tion development [20].
Presumably, entry inhibitors must be present at suffi-
ciently high concentrations at the cell surface of immune
targets in the genital tract following intercourse, whereas
RTIs must be retained intracellularly within HIV target
cells following coitus. Both types of drugs must be ac-
cessible to resident immune cells and to cells recruited
into the genital tract in response to chemokines and
other inflammatory signals released in response to sex
or other environmental stimuli. To model these clinical
scenarios in vitro, the ability of drugs to retain anti-HIV
activity if cells were washed with seminal plasma (SP)
(simulating a washout following exposure to ejaculate)
and to protect drug-naive T cells (representing newly re-
cruited immune cells) co-cultured with explant tissue
that had been pretreated with drug, were evaluated. We
then extended the studies to in vivo models and tested
the PK/PD relationships in CVL and cervical biopsies
obtained from macaques following 14-day treatment
with an IVR delivering IQP-0528 [16]. Taken together,
the results of the studies indicate that combinations of
drugs with complementary PK/PD properties and for-
mulated for sustained drug delivery may provide the
greatest protection against sexual transmission of HIV.
Results and discussion
Differential intracellular drug retention
To model the potential effects that an ejaculate may
have on drug activity in vitro, we exposed Jurkat-Tat-
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TDF, IQP-0528, DPV, MVC and PIE12 for 24 h and
then either washed the cells with medium containing
10% SP, medium alone or no wash (control) prior to
challenge with HIV-1Ba-L. The highest concentrations
of drugs tested had no impact on cell viability
assessed by measuring the metabolism of 3-(4,5-di-
methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) (data not shown).
Consistent with prior studies when HIV was added to
cultures in the absence or presence of SP [21], TDF (at
concentrations greater than or equal to 0.1 μM) retained its
antiviral activity and was not impacted by washing with
either medium or SP (Figure 1a). This likely reflects the
rapid uptake and intracellular metabolism of the drug to
TFV-diphosphate (TFV-DP), which has a long intracellular
half-life [22].
In contrast, there was a significant reduction in inhibi-
tory activity for the NNRTIs and entry inhibitors, as
illustrated by a shift to the right in the dose response
curves if the cells were washed with either medium or
SP prior to viral challenge (Figure 1b-e). At the highest
concentrations tested (10 and 100 μM, neither IQP-0528A
0.001 0.01 0.1 1 10






















n o w a sh

























































m e d iu m w a sh













[ P I E 
#
#
[ I Q P - 0 5
Figure 1 Differential intracellular drug retention. JT-CCR5 cells were ex
TDF + IQP-0528) in complete medium for 24 h prior to challenge with app
presence of drug (black lines, closed squares), after washing with serum-fre
serum-free medium containing 10% seminal plasma (SP) (grey lines, open
culture supernatants 6 days post-infection. Data are presented as percent i
are means ± SEM obtained from at least three independent experiments w
(one experiment).or MVC completely protected the cells from infection,
although it is possible that higher concentrations might
overcome the washout effect. The shift in the dose
response curve for the NNRTIs is consistent with the
dynamic movement of drugs into and out of cells in re-
sponse to intracellular and extracellular concentration
gradients [23]. Notably, DPV was affected more by a
wash with 10% SP compared to medium, suggesting that
the drug may bind to seminal proteins, as has been re-
ported for serum proteins [24]. For example, 1 μM DPV
failed to inhibit HIV infection if the cells were washed
with SP prior to HIV challenge, whereas the same con-
centration of drug provided 73.9 ± 13.8% (mean ± SEM)
protection if the cells were washed with medium alone
(Figure 1c). Importantly, the combination of equal
concentrations of TDF and IQP-0528 resulted in HIV
inhibition comparable to what was observed following
exposure to TDF alone. This suggests that the presence
of a NNRTI does not impact TDF uptake and intracellu-
lar retention (Figure 1f ).
The CCR5 co-receptor antagonist MVC, which has
previously been shown to be active in the low nanomo-
lar range if drug is present throughout the experiment0.001 0.01 0.1 1 10
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posed to drug (A- TDF; B- IQP-0528; C- DPV; D- MVC; E- PIE12; F-
roximately 103 TCID50 HIV-1Ba-L. Virus challenge was performed in the
e medium (hatched black lines, open triangles) or after washing with
circles). HIV replication was assessed by measuring p24 antigen in
nhibition relative to cells challenged in the absence of treatment and
here each condition was tested in triplicate, except where noted #
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current experimental conditions (cells washed 2 h after
viral inoculation) (Table 1). When MVC was re-added to
cultures following the washing step, the antiviral activity
observed was consistent with published data [25] (not
shown). To determine whether the higher concentra-
tions of MVC needed in these studies might reflect the
greater expression of CCR5 at the cell surface of
JT-CCR5 cells compared to primary cells, parallel exper-
iments were conducted using human PBMCs. Flow cy-
tometry confirmed greater expression of CCR5 on JT-
CCR5 cells compared to PBMCs (99% of JT-CCR5 cells
expressed CCR5 compared to 30-40% of PHA-activated
PBMCs), but there was no difference in the antiviral ac-
tivity of MVC (data not shown). Moreover, the inhibitory
activity of MVC was significantly reduced if the JT-
CCR5 cells were washed with medium or medium con-
taining SP prior to infecting with virus (Figure 1d). The
finding that higher concentrations of MVC are needed if
drug is only present prior to HIV exposure combined
with the loss of activity observed following a wash with
medium or SP suggest that protection will require sus-
tained MVC delivery.
There was also a loss of activity for PIE12 following
washing, but complete inhibition of HIV infection was
still achieved at concentrations less than 1μM, even after
a wash with SP (Figure 1e). The membrane-localizing
cholesterol group, which is conjugated to the PIE12-
trimer by a PEG linker, may contribute to potent anti-
viral activity of this entry inhibitor even after wash-out
with medium or SP [20].
Co-culture model
Cell cultures provide a first approximation of potential
drug activity, but do not reflect the complexities found
in human genital tract tissue. While direct challenge of
tissue would provide information about how well the
drug can protect resident target cells from HIV, reprodu-
cibility, variability in the number and activation status of
immune cells, and the need to work with fresh tissueTable 1 Human cervical tissue as a drug reservoir for protecti
Drug JT-CCR5 Infection
IC50(μM) IC90(μM)
TDF 0.04 ± 0.01 0.13 ± 0.02
IQP-0528 0.19 ± 0.07 0.43 ± 0.16
DPV 0.01 ± 0.01 0.03 ± 0.02
MVC 1.98 ± 0.85 54.5 ± 13.8
Chol-PIE12 trimer < 0.0001 0.009 ± 0.007
TDF + IQP-0528 0.01 ± 0.01 0.03 ± 0.02
JT-CCR5 cells were challenged with HIV-1Ba-L in the presence of indicated drugs. Alt
drugs for 24 h, washed, and then co-cultured with JT-CCR5 cells prior to challenge
with each condition tested in triplicate and are means ± SEM.has limited the feasibility of using direct challenges as a
model of PD in clinical trials [26,27]. To circumvent
these problems, we developed a model to test how well
tissue serves as a reservoir to protect immune cells that
might be recruited into the genital tract in response to
various environmental stimuli [13]. Human ectocervical
explant tissue was treated ex vivo with varying concen-
trations of the panel of drugs described above, washed,
and then minced and co-cultured with JT-CCR5 cells
prior to being challenged with HIV-1Ba-L (Figure 2a).
The ability of tissue-associated drug to protect the co-
cultured cells from infection was monitored by p24
ELISA. The concentrations of drugs used during tissue
exposure that inhibited 50% (IC50) and 90% (IC90) of
HIV infection in this co-culture model were compared
to the concentrations needed to inhibit direct infection
of JT-CCR5 cells (Table 1). Cells co-cultured with tissue
that had been exposed to TDF were not protected from
viral infection, which is consistent with the intracellular
trapping of TFV-DP and the data presented in Figure 1.
MVC also failed to protect co-cultured T cells.
In contrast, pretreatment of explant tissue ex vivo with
IQP-0528, DPV or PIE12 provided significant protection
against infection of the co-cultured T cells, indicating
the potential ability of the drugs to protect newly re-
cruited immune cells. The multilayered nature of the tis-
sue likely provides a sufficiently large reservoir of these
drugs, which are released to protect co-cultured T cells
but not during the short washing step prior to co-
culture. The combination of equal concentrations of
TDF and IQP-0528 provided complete protection in
both the washout (Figure 1f ) and the co-culture (Table 1)
model. In the former model, efficacy reflects the resist-
ance of intracellular TFV-DP to a wash, whereas in the
latter, the protection reflects the rapid transit of IQP-
0528 out of the tissue and into the JT-CCR5 cells. These
findings illustrate the advantage of combining drugs with
complementary PK/PD properties.
To address the feasibility of applying the co-culture
model to clinical studies, we compared co-cultures ofon of T cells
Co-culture JT-CCR5 & explant tissue
IC50(μM) IC90(μM)
>10.0 >10.0
2.9 ± 0.7 10.1 ± 0.7
0.4 ± 0.2 1.1 ± 0.3
>100 >100
0.008 ± 0.004 0.09 ± 0.01
0.5 ± 0.2 9.5 ± 0.8
ernatively, human ectocervical explants were exposed to the same panel of
with virus. IC50 and IC90 values were calculated from at least two experiments
BA
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Figure 2 Co-culture model. (A) Schematic representation of model. Drug-exposed human explant tissue is washed, minced and co-cultured
with HIV-susceptible cells (JT-CCR5 cells) for 72 h to allow drug present in the tissue to be transported into cells prior to challenge with HIV-1Ba-L.
(B) Ectocervical explants were exposed to indicated concentrations of IQP-0528 for 24 hours. Tissue was washed and either immediately co-
cultured with JT-CCR5 cells for 72 h prior to challenge or stored at -80C for 24 h or 7 d before co-culture and challenge. HIV replication was
assessed by measuring p24 antigen in culture supernatants 7 days post-infection. Data are presented as the percentage infection relative to co-
cultures challenged in the absence of drug treatment and are means ± SEM obtained from at least two independent experiments using tissue
from different donors where each condition was tested in triplicate.
Mesquita et al. Retrovirology 2013, 10:113 Page 5 of 11
http://www.retrovirology.com/content/10/1/113tissue frozen and stored at −80°C (for 24 h or 7 days)
following drug treatment to co-cultures of fresh tissue.
Fresh ectocervical explants were treated with IQP-0528,
washed and then either stored at −80°C or immediately
processed as described above and co-cultured with JT-
CCR5 T cells. IQP-0528 was protective under all of these
conditions (Figure 2b).
PK/PD of IQP-0528 IVR in pig-tailed macaques
Treatment of tissue with drug ex vivo may not reflect
the tissue levels achieved in vivo. Therefore, we applied
our models to biological samples obtained from non-
human primates (NHPs) that participated in a 14-day
study of a 10% (w/w) polyurethane IVR that delivered an
average of 200 μg/day of IQP-0528 [16]. Four animals
were treated with the active ring and 2 with placebo IVR
devices. We examined drug levels (PK) and antiviral
activity (PD) in CVL and cervical biopsies (using the co-
culture model) obtained proximal and distal to the site










IQP-0528 concentration in cervicovaginal lavage (CVL) samples (μg/mL) or in proximring insertion. Significantly higher concentrations of
drug were detected in Day 14 proximal and distal
biopsies compared to Day 7 biopsies (Table 2; Mann
Whitney test; p = 0.001), indicating that the NNRTI
accumulated in genital tract tissue over time and may
provide a local source of drug for recruited cells. In con-
trast, there was little difference in levels measured in
CVL between Day 7 and 14. This is consistent with what
we observed in a study comparing different loading
doses in which rings loaded with high concentrations of
pyrimidinediones displayed near time-independent re-
lease rates, likely due to saturation-dependent drug
release [16].
To determine the antiviral activity of luminal drug,
which represents drug released from the IVR that is
never taken up by or transits out of the tissue and cells,
TZM-bl cells were challenged with HIV-1Ba-L in the
presence of two different dilutions (1:10 and 1:100) of
the CVL samples. Consistent with the concentration of
drug recovered (Table 2), which at both CVL dilutionsMacaques Mean ±
SEMPKP1 PHC2 PTE2
1290 730 1930 1360 ± 249
510 600 1050 940 ± 250
1.01 6.16 5.24 3.36 ± 1.36
36.68 12.46 29.87 28.08 ± 5.39
0.66 0.79 1.50 0.85 ± 0.23
2.38 5.66 21.62 14.65 ± 6.35
al or distal cervical biopsy tissue samples (ng/mg of tissue).
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2.7 ng/ml (not shown), cells challenged with virus in the
presence of CVL were significantly protected from infec-
tion (Figure 3a and b). There was a small drop in activity
in 1:100 dilution CVL samples. In contrast, no antiviral
activity was found in the baseline CVL or samples
collected from animals exposed to placebo IVRs.
Subtype C HIV is one of the most prevalent in East
and South Africa, India, China and Nepal [28]. To fur-
ther examine the antiviral activity of drug released from
the IVR, we expanded the studies with CVL and used a
more stringent ex vivo model. TZM-bl cells were
cultured in transwell™ inserts and exposed to diluted
gamma-irradiated CVL applied to the basolateral side.
Gamma irradiation was used to prevent microbial con-
tamination and had no impact on drug activity (data not
shown). The cells and CVL were incubated overnight to
allow drug equilibration prior to apical challenge with
two different amounts (10 or 100 TCID50) of CCR5-
tropic HIV-1 subtype C (isolate 97USNG30). CVL sam-
ples collected from animals treated with the IQP-0528
IVR provided at least partial protection against 10
TCID50, with samples collected at day 7 from 2 of 4 ani-
mals and at day 14 from 3 of 4 animals, affording
complete inhibition in this assay (Table 3). Notably, the
three samples affording protection had the highest drug
concentrations at day 14. When cells were challenged
with 100 TCID50, complete inhibition was observed only
for samples collected at day 14 from the two animals
with higher CVL IQP-0528 levels (PMD2 and PTE2). No
protection was observed with samples collected at base-
line or from animals treated with placebo rings.
To evaluate IQP-0528 PD in biopsy tissue samples, bi-
opsies collected from sites proximal and distal to the
IVR insertion at baseline, 7 and 14 days post ringCVL diluted 1:10A B























125 IQP-0528 (n=4)Placebo (n=2)
Figure 3 Antiviral activity in NHP CVL. TZM-bl cells were challenged wit
1:100 (B) dilutions of CVL collected from pig-tailed macaques at Day 0 (bas
exposed to IVRs loaded with 10% (w/w) IQP-0528 (squares) and two anima
measuring luciferase activity 48 h post-challenge. Data are presented as the
of CVL and are means obtained from two independent experiments where
for the group.application were minced and co-cultured with PHA-
activated human PBMC prior to challenge with HIV-1Ba-L.
Co-culture with proximal biopsies yielded viral inhib-
ition of 53.0% (day 7) and 71.7% (day 14), whereas
distal biopsy co-cultures were relatively less protected,
with 42.3% (day 7) and 59.2% (day 14) inhibition
(Figure 4). The activity correlated with drug levels re-
covered (Table 2; Figure 5) with greater correlation ob-
served with proximal (Spearman ρ = 0.86; p = 0.0006)
than distal (Spearman ρ = 0.62; p = 0.03) biopsies, pos-
sibly reflecting less homogenous drug distribution as
the distance to the site of release increases. One caveat
of this analysis is that PK was measured using one set
of biopsies and PD assessed in a different sample.
The combination of in vitro and ex vivo models
evaluated in these studies provide a more comprehensive
assessment of the potential activity of candidate microbi-
cides under conditions that may better simulate clinical
application of the drug. Specifically, the models allow for
the assessment of key molecular properties that define
the PD of the drug, including how fast and to what
extent drugs traffic in and out of tissue and whether
sufficient drug is retained at the site of its activity after
a potential washout following exposure to SP. These
models could also provide additional rationale for
selecting drugs to be co-formulated for HIV prevention.
Combinations that target different steps in the viral life
cycle, act in different compartments (luminally, cell sur-
face, or intracellularly) and, as indicated by the models
here, exhibit complementary molecular properties that
influence the cellular and tissue biodistribution of the
drug may be optimal. By quantifying drug concentration
and antiviral activity, combinations and target drug con-
centrations with the greatest potential for HIV preven-
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CVL diluted 1:100
0 7 14
h approximately 103 TCID50 HIV-1Ba-L in the presence of 1:10 (A) or
eline) and 7 and 14 days post-insertion of IVR. Four animals were
ls received placebo IVRs (circles). HIV infection was assessed by
percent inhibition relative to control cells challenged in the absence
each condition was tested in triplicate. The line indicates the mean
ProximalA B






















100 IQP - 0528 (n=4)Placebo (n=2)
Figure 4 Antiviral activity in NHP cervical tissue. Proximal (cervical; A) a
14 days post-insertion of IVR were minced and co-cultured with PHA-activa
bottomed 96-well plates within 24 h of collection in the presence of cultur
for 72 h prior to challenge with HIV-1Ba-L (approximately 10
3 TCID50). The in
with serum-free medium and incubated for 7–10 days at 37°C. Four anima
two animals received placebo IVRs (circles). HIV replication was assessed by
inhibition relative to control cells challenged in the absence of tissue co-cu
condition was tested in triplicate; the line indicates the mean for the group
Table 3 Antiviral activity of cervicovaginal lavage (CVL)
against primary HIV-1 subtype C (97USNG30) in dual
chamber system
HIV-1 Subtype C (97USNG30)
Animal Day 10 TCID50 100 TCID50
IQP 1 (PMD2)
0 + + + + + +
7 - - - + - -
14 - - - - - -
IQP 2 (PKP1)
0 + + + + + +
7 + - + + + +
14 - - + + + +
IQP 3 (PHC2)
0 + + + + + +
7 - - - + + +
14 - - - + + +
IQP 4 (PTE2)
0 + + + + + +
7 + - + + + +
14 - - - - - -
Placebo 1 (PZA2)
0 + + + + + +
7 + + + + + +
14 + + + + + +
Placebo 2 (PUG2)
0 + + + + + +
7 + + + + + +
14 + + + + + +
TZM-bl cells were exposed to CVL obtained at the indicated times (Day 0
(baseline), Day 7 or Day 14) from macaques treated with the IQP-0528 or
placebo intravaginal ring and challenged with HIV (10 or 100 TCID50) in
triplicate. Culture wells with luciferase activity above or below background
levels from CVL exposure alone are marked (+) or (−), respectively.
Mesquita et al. Retrovirology 2013, 10:113 Page 7 of 11
http://www.retrovirology.com/content/10/1/113TDF and IQP-0528 could provide greater protection
than achieved by either drug alone. TDF would protect
resident cells even after a partial washout of the NNRTI
by ejaculate because its active metabolite, TFV-DP, is
retained intracellularly, whereas the tissue reservoirs
of IQP-058 (or presumably, dapivirine) would provide
sufficient drug to protect cells recruited into the genital
tract.
There were also notable differences between the two
entry inhibitors evaluated in these models. PIE12
retained substantial activity in both models, possibly
reflecting its potency, membrane-localizing cholesterol
group, and larger molecular weight compared to small
molecules (~9 kDa) that likely slows diffusion into and
out of tissues. In contrast, MVC, which was present
prior to or during viral inoculation but was not re-added
to the culture medium post infection, was readily
washed out by SP (or medium) and failed to protect T
cells in the co-culture model suggesting that, in the ab-
sence of sustained delivery, MVC may not have the PK
properties needed to protect against infection. A recent
study showed that the efficacy of MVC may be underes-
timated by measuring plasma viral loads because virus
that is blocked from entering the cells may reenter the
extracellular space [29]. However, it is unlikely that this
property contributed to the findings of reduced activity
in the models described here where the cells and tissue
were washed.
There are several unique attributes to the co-culture
model of PK/PD relationships. While direct challenge of
biopsy tissue offers theoretical advantages, it has proven
to be technically challenging. The co-culture model cir-






















100 IQP - 0528 (n=4)Placebo (n=2)
Distal
nd distal (introitus; B) biopsies collected at Day 0 (baseline) and 7 and
ted human PBMC (1x105 cells/well) in triplicate wells of round-
e medium used during shipment. Co-cultures were incubated at 37°C
oculum was removed and co-cultured tissue and cells washed thrice
ls were exposed to IVRs loaded with 10% (w/w) IQP-0528 (squares) and
measuring p24 levels by ELISA. Data are presented as the percent
lture and are means obtained from one experiment where each
.
BA P r o x im a l
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Figure 5 PK/PD correlations. Inhibition of HIV-1Ba-L infection in co-cultures of proximal (A) and distal (B) biopsies was correlated with IQP-0528
levels in biopsy tissue. Crosses represent biopsies obtained from animals exposed to placebo IVRs. Open and closed squares represent biopsies
collected from animals exposed to IQP-0528 IVRs at 7 and 14 days post-IVR insertion, respectively. The Spearman correlation coefficient (ρ)
is indicated.
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in the number and activation status of the resident im-
mune cells. Second, it can be applied to frozen tissue,
whereas direct challenge should be performed with
fresh tissue, as reproducibility infecting tissue that has
previously been frozen has been poor compared to
fresh tissue (Charlene Dezzutti; personal communica-
tion) and frozen tissue does not support HIV replica-
tion as well as fresh tissue [27]. Finally, in the case of
NHP studies, the challenge can be performed with
HIV, rather than SHIV or SIV because the NHP tissue
is serving primarily as the source of drug, and not pro-
viding the immune target cells. Thus, co-cultures can
be performed with human PBMCs (or a T cell line) as
in Figure 2 and Table 1. The model assay can be easily
expanded to test primary isolates, different clades, and
founder viral populations. Challenges can also be per-
formed with virus mixed with semen or seminal
plasma.Conclusions
Drug combinations for topical prevention of HIV trans-
mission have been proposed for more than a decade
[30-32]. Potential advantages include the decreased like-
lihood of selecting for resistant viral variants, protection
against resistant variants circulating in the community,
and greater efficacy resulting from the synergy of target-
ing different stages of the HIV life cycle. The data pre-
sented here indicate that in addition to these attributes,
combining drugs with complementary physical proper-
ties and biodistribution profiles could be key to protect-
ing cells resident in the genital tract at the time of
sexual exposure and those subsequently recruited into
the mucosa. Importantly, these data highlight the im-
portance of model assay systems to test candidate ARVs
and ARV combinations.Methods
Cells and viruses
Jurkat-Tat-CCR5 (JT-CCR5) cells were provided by
Quentin Sattentau (Sir William Dunn School of
Pathology, University of Oxford, Oxford, United Kingdom)
and TZM-bl cells were obtained from the NIH AIDS
Reagent Program and were both cultured as previously de-
scribed [33]. PBMCs were obtained by density gradient cen-
trifugation of healthy donor blood (venipuncture) diluted in
Hanks balanced saline solution (HBSS) using Ficoll-paque™
Plus (GE Healthcare, Uppsala, Sweden) and activated by
3 day culture (5×105cells/mL) in RPMI-1640 medium
containing L-glutamine, 10% fetal bovine serum (FBS),
2 mM L-glutamine, 100 U/mL penicillin (herein referred to
as complete medium), supplemented with 5 μg/mL
Phytohemagglutinin (PHA) and subsequently cultured
in complete medium supplemented with 50 U/mL
interleukin (IL)-2 at 37°C in a humidified atmosphere
containing 5% CO2. The laboratory-adapted HIV-1Ba-L
(CCR5-utilizing strain) was grown as previously de-
scribed [33]. The Clade C strain 97USNG30 (NIH
AIDS Research and Reference Reagent Program) was
grown in human PBMCs. HIV stocks were stored in
liquid nitrogen or at −70°C.Drugs and reagents
Tenofovir disoproxil fumarate (TDF) was provided by
Gilead (Foster City, CA). The pyrimidinedione IQP-0528
was provided by ImQuest BioSciences Inc. and com-
pounded at 10 wt% in Tecoflex® EG-85A polyurethane
(PU) with a Haake-MiniLab extruder at 150°C (Thermo
Scientific) and pelletized using a variable-speed pelletizer
(Randcastle Extrusion). The pelletized extrudate was
injection molded into IVRs (25 mm outer diameter
and 5 mm cross-section) using a Babyplast 6/10P micro-
injection molding system (ALBA Enterprises) with injection
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mass of 1.27 g ± 5 mg (mean ± SD, N = 10). Dapivirine
(DPV) and Maraviroc (MVC) were provided by the
International Partnership for Microbicides (IPM) and the
cholesterol-PIE12 trimer (PIE12) was synthesized at the
University of Utah [20]. Human semen was purchased from
Lee Biosolutions, Inc. (St Louis, MO). Semen was clarified
by centrifugation at 500 g for 10 min and the supernatant
(seminal plasma) divided into aliquots and stored at −80°C.
Toxicity assessment
JT-CCR5 cells were exposed to the highest concentrations
of the panel of drugs for 24 h in 96-well round-bottomed
plates (2×105 cells/well). Plates were centrifuged at 500 g
for 5 min and supernatants were discarded prior to each of
three washing steps with 200 μL of medium. Cell viability
was assessed using the CellTiter 96 cell proliferation assay
(MTS; Promega).
Intracellular drug retention
JT-CCR5 T cells in 24-well plates (1×106 cells/well) were
exposed to varying concentrations of drugs diluted in
complete medium for 24 h. The cells were then washed
with 10 mL of medium, medium containing 10% human
seminal plasma (SP), or not washed and then washed
cells were resuspended in complete medium prior to
transfer to round-bottomed 96-well plates and exposed
to 103 TCID50 (50% tissue culture infective dose)
HIV-1Ba-L for 2 h. Plates were centrifuged at 500 g for
5 min and supernatants were removed prior to each of 3
washing steps with 200 μL of medium. Cells were subse-
quently cultured in 200 μL complete medium and HIV
replication was assessed 6 d post-infection by measuring
p24 antigen by ELISA [34].
Co-culture model for assessment of drug PD
Cervical tissue was collected from pre-menopausal
women undergoing therapeutic hysterectomies at the
Albert Einstein–Montefiore Weiler Hospital (Bronx, NY,
USA) under an IRB exempt protocol. Ectocervical tissue
was cut into explants of approximately 3×3×3 mm
[33,35] prior to 24 h exposure to panel of unformulated
drugs in 24-well plates. Extracellular free drug was re-
moved by immersing explants in phosphate buffered sa-
line (PBS) containing Ca2+ before mincing explants into
fragments smaller than 1 mm, which were resuspended
in 200 μL complete medium and co-cultured with
JT-CCR5 cells (1×105 cells/well) in triplicate wells of
round-bottomed 96-well plates. Co-cultures were incu-
bated at 37°C for 72 h to allow released drug to be trans-
ferred from the tissue to T cells prior to challenge with
HIV-1Ba-L (approximately 10
3 TCID50). The inoculum
was removed and co-cultured tissue and cells washedthrice with medium. HIV replication was assessed by
measuring p24 levels by ELISA (Figure 2a).
Non-human primate (NHP) studies
A 14-day IQP-0528 IVR biodistribution study using pig-
tail macaque monkeys was performed following proto-
cols approved by the CDC Institutional Animal Care
and Use Committee according to the Guide for the Care
and Use of Laboratory Animals as previously described
[36]. Briefly, animals were anesthetized with ketamine
(3-10 mg/kg) prior to all collection procedures. A total
of six macaques were used with two animals receiving
placebo IVR and four animals receiving IQP-0528 (10%
w/w) IVR. A pediatric speculum and forceps were used
to insert IVRs in the posterior vagina proximal to the
ectocervix on day 0 and left in place for 14 days. Tissue
samples were collected with biopsy forceps (Miltex
Townsend # 30–1445) near the vaginal introitus (distal
to the ring) and the ectocervix (proximal to the ring)
and shipped at 4°C to the Herold laboratory overnight.
CVL samples were obtained by washing the vaginal vault
with 5 mL normal saline; CVL samples were divided into
aliquots, shipped and stored at −80°C.
Measurement of IQP-0528 levels
IQP-0528 in biological samples was extracted and
analyzed using LC-MS/MS at the Center for Human
Toxicology (Utah). The lower limit of quantification
(LLOQ) for this assay was 1 ng/mL of matrix. To con-
vert weight/weight concentrations of IQP-0528 (nano-
grams IQP-0528 per milligram of vaginal fluid or tissue)
to molarity (μM), vaginal fluid and tissue densities of
1.0 g/mL were assumed.
Antiviral activity of CVL
TZM-bl cells were plated at 3x104/well and allowed
to adhere overnight before exposure to 103 TCID50
HIV-1Ba-L in the presence of CVL diluted 1:10 and 1:100
in complete DMEM in triplicate wells. Virus and drugs
were left in culture for 48 h at 37°C and then removed
by washing once with 200 μl PBS. Cells were lysed in
100 μl luciferase cell culture lysis reagent (Promega) and
stored at −80°C until assessed for luciferase activity
using luciferase assay buffer (Promega). Alternatively,
TZM-bl cells were plated at 5x103/well in polyester
transwell™ inserts with 1.0 μm pore size (Corning) and
exposed basolaterally to CVL diluted 1:20 in complete
DMEM overnight before apical challenge with the
CCR5-tropic subtype C HIV isolate 97USNG30 (0, 10
and 100 TCID50). Wells with luciferase activity above
background average + 2 standard deviations (cells ex-
posed to CVL but no virus) were considered positive. To
avoid contamination, frozen CVL was Gamma-irradiated
on dry ice (1KGy) prior to use.
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Proximal and distal biopsies were collected and placed
in 200 μL of complete medium and shipped to the
Herold laboratory at 4°C. Biopsies were minced without
washing and co-cultured with activated human PBMC in
the presence of culture medium used during transport.
Challenge and assessment of HIV replication were per-
formed as described for human cervical explant tissue
(Figure 2a).
Statistical analyses
Analyses were performed using GraphPad Prism
(GraphPad Software, Inc.). Differences between treat-
ment conditions were compared by Kruskal-Wallis
or unpaired t-test.
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